Scleroderma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]

Overview

There are no established measures for the secondary prevention of scleroderma. However, effective measures for the secondary prevention of pulmonary arterial hypertension and scleroderma renal crisis in patients with scleroderma include screening.

Secondary Prevention

There are no established measures for the secondary prevention of scleroderma. However, effective measures for the secondary prevention of pulmonary arterial hypertension and scleroderma renal crisis in patients with scleroderma include:^[1]^[2]^[3]
- Annual screening with trans thoracic echocardiogram (TTE) and pulmonary function tests (PFTs) for pulmonary hypertension.
- Regular blood pressure monitoring at home for early detection of scleroderma renal crisis.

References

↑ McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J (April 2009). “ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association”. J. Am. Coll. Cardiol. 53 (17): 1573–619. doi:10.1016/j.jacc.2009.01.004. PMID 19389575.
↑ Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E, Humbert M, Langleben D, Mathai SC, Saggar R, Visovatti S, Altorok N, Townsend W, FitzGerald J, McLaughlin VV (December 2013). “Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension”. Arthritis Rheum. 65 (12): 3194–201. doi:10.1002/art.38172. PMC 3883571. PMID 24022584.
↑ Khanna D, Denton CP (June 2010). “Evidence-based management of rapidly progressing systemic sclerosis”. Best Pract Res Clin Rheumatol. 24 (3): 387–400. doi:10.1016/j.berh.2009.12.002. PMC 2884006. PMID 20534372.

Template:WH Template:WS

[pmid19389575-1] McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J (April 2009). “ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association”. J. Am. Coll. Cardiol. 53 (17): 1573–619. doi:10.1016/j.jacc.2009.01.004. PMID 19389575.

[pmid24022584-2] Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, Hachulla E, Humbert M, Langleben D, Mathai SC, Saggar R, Visovatti S, Altorok N, Townsend W, FitzGerald J, McLaughlin VV (December 2013). “Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension”. Arthritis Rheum. 65 (12): 3194–201. doi:10.1002/art.38172. PMC 3883571. PMID 24022584.

[pmid20534372-3] Khanna D, Denton CP (June 2010). “Evidence-based management of rapidly progressing systemic sclerosis”. Best Pract Res Clin Rheumatol. 24 (3): 387–400. doi:10.1016/j.berh.2009.12.002. PMC 2884006. PMID 20534372.

[1]

[2]

[3]

Scleroderma secondary prevention

Overview

Secondary Prevention

References

Looking for the patient version?